Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The preparation is standardised prior to use, allowing researchers to work with a consistent peptide composition and eliminating variability associated with solution preparation
The Three Pricing Tiers: Research Peptide vs Online vs Medical Clinic The BPC-157 market has three distinct tiers with different legal status, supervision, and quality control
| Agent | FDA Approval | Mean Weight Loss (RCT) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | 14.9% at 68 weeks (STEP-1, N=1,961) [9] | Subcutaneous weekly | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [11] | Subcutaneous weekly | | AOD-9604 1 mg oral | No | ~2.8 kg at 12 weeks (Phase IIb, N=300 approx.) [1] | Oral (not currently compounded) | The weight-loss magnitude from the single Phase IIb AOD-9604 trial is substantially smaller than what STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) demonstrated in larger, longer trials
Lifestyle & timeline: Do you have time to follow a progressive rehab plan and protect the area while it heals
Causes lipohypertrophy
The structural basis for this stability is not fully elucidated but may relate to its high proline content (3 consecutive Pro residues) which confers rigidity and protease resistance
